AbbVie Inc.
ABBVAPI behind this page
ABBV Q4 2025 request
Playground key active
/api/financials?ticker=ABBV&year=2025&quarter=4
Pick an endpoint and run the request.Income Statement
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | 16,618 | 15,102 | +10.0% |
| Cost of Revenue | 4,552 | 4,396 | +3.5% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Foreign Exchange Forward | 3 | -32 | +109.4% |
| Selling, General & Administrative | 3,895 | 3,855 | +1.0% |
| Research And Development Expense Excluding Acquired In Process Cost | 2,579 | 6,774 | -61.9% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 1,265 | 1,574 | -19.6% |
Show Counterparty Name breakouts |
|||
| Other individually insignificant arrangements · Collaborative Arrangement | -2,964 | -113 | -2523.0% |
| Total Costs & Expenses | 12,074 | 16,592 | -27.2% |
| Operating Income | 4,544 | -1,490 | +405.0% |
| Interest Income Expense Nonoperating Net | 655 | 610 | +7.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Treasury Lock | 36 | 41 | -12.2% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | -37 | -33 | -12.1% |
| Foreign Currency Transaction Gain Loss Before Tax | 11 | 19 | -42.1% |
| Other Non-Operating Income (Expense) | 1,210 | 150 | +706.7% |
| Income Before Taxes | 2,668 | -2,269 | +217.6% |
| Income Tax Expense (Benefit) | 853 | -2,246 | +138.0% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income | 4 | 8 | -50.0% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | 8 | 7 | +14.3% |
| Net Income | 1,815 | -23 | +7991.3% |
| Net Income Loss Attributable To Noncontrolling Interest | -1 | -1 | 0.0% |
| Net Income | 1,816 | -22 | +8354.5% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | 29 | -103.4% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging | 29 | 26 | +11.5% |
| Retained Earnings | 1,816 | -22 | +8354.5% |
| EPS (Basic) | 1.02 | -0.01 | +10300.0% |
| EPS (Diluted) | 1.02 | -0.02 | +5200.0% |
| Wtd Avg Shares (Basic) | 0 | 0 | — |
| Wtd Avg Shares (Diluted) | 1 | 1 | 0.0% |
| Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| All other | 617 | 752 | -18.0% |
| Alphagan/Combigan · Eye Care | 54 | 78 | -30.8% |
| Alphagan/Combigan · Non Us | 36 | 37 | -2.7% |
| Alphagan/Combigan · US | 18 | 41 | -56.1% |
| Botox Cosmetic · Aesthetics | 717 | 687 | +4.4% |
| Botox Cosmetic · Non Us | 297 | 258 | +15.1% |
| Botox Cosmetic · US | 420 | 429 | -2.1% |
| Botox Therapeutic · Neuroscience | 990 | 873 | +13.4% |
| Botox Therapeutic · Non Us | 162 | 143 | +13.3% |
| Botox Therapeutic · US | 828 | 730 | +13.4% |
| Creon · US | 385 | 388 | -0.8% |
| Duodopa · Neuroscience | 92 | 108 | -14.8% |
| Duodopa · Non Us | 75 | 84 | -10.7% |
| Duodopa · US | 17 | 24 | -29.2% |
| Elahere · Oncology | 182 | 148 | +23.0% |
| Elahere · US | 154 | 146 | +5.5% |
| Epkinly · Non Us | 29 | 4 | +625.0% |
| Epkinly · Oncology | 81 | 40 | +102.5% |
| Humira · Immunology | 1,246 | 1,682 | -25.9% |
| Humira · Non Us | 349 | 436 | -20.0% |
| Humira · US | 897 | 1,246 | -28.0% |
| Imbruvica · Oncology | 671 | 848 | -20.9% |
| Imbruvica · US | 469 | 625 | -25.0% |
| Juvederm Collection · Aesthetics | 249 | 279 | -10.8% |
| Juvederm Collection · Non Us | 142 | 159 | -10.7% |
| Juvederm Collection · US | 107 | 120 | -10.8% |
| Linzess/Constella · Non Us | 12 | 10 | +20.0% |
| Linzess/Constella · Other Key Products | 175 | 233 | -24.9% |
| Linzess/Constella · US | 163 | 223 | -26.9% |
| Lumigan/Ganfort · Eye Care | 104 | 119 | -12.6% |
| Lumigan/Ganfort · Non Us | 57 | 61 | -6.6% |
| Lumigan/Ganfort · US | 47 | 58 | -19.0% |
| Mavyret · Non Us | 161 | 154 | +4.5% |
| Mavyret · Other Key Products | 324 | 291 | +11.3% |
| Mavyret · US | 163 | 137 | +19.0% |
| Other Aesthetics · Aesthetics | 320 | 332 | -3.6% |
| Other Aesthetics · Non Us | 36 | 42 | -14.3% |
| Other Aesthetics · US | 284 | 290 | -2.1% |
| Other Eye Care · Eye Care | 294 | 329 | -10.6% |
| Other Eye Care · Non Us | 105 | 106 | -0.9% |
| Other Eye Care · US | 189 | 223 | -15.2% |
| Other Neuroscience · Neuroscience | 47 | 56 | -16.1% |
| Other Neuroscience · Non Us | 3 | 5 | -40.0% |
| Other Neuroscience · US | 44 | 51 | -13.7% |
| Ozurdex · Eye Care | 128 | 120 | +6.7% |
| Ozurdex · Non Us | 96 | 84 | +14.3% |
| Ozurdex · US | 32 | 36 | -11.1% |
| Qulipta · Neuroscience | 288 | 201 | +43.3% |
| Qulipta · Non Us | 43 | 15 | +186.7% |
| Qulipta · US | 245 | 186 | +31.7% |
| Rinvoq · Immunology | 2,374 | 1,834 | +29.4% |
| Rinvoq · Non Us | 665 | 487 | +36.6% |
| Rinvoq · US | 1,709 | 1,347 | +26.9% |
| Skyrizi · Immunology | 5,006 | 3,778 | +32.5% |
| Skyrizi · Non Us | 651 | 466 | +39.7% |
| Skyrizi · US | 4,355 | 3,312 | +31.5% |
| Ubrelvy · Neuroscience | 339 | 303 | +11.9% |
| Ubrelvy · Non Us | 7 | 7 | 0.0% |
| Ubrelvy · US | 332 | 296 | +12.2% |
| Venclexta · Non Us | 378 | 342 | +10.5% |
| Venclexta · Oncology | 710 | 655 | +8.4% |
| Venclexta · US | 332 | 313 | +6.1% |
| Vraylar · Neuroscience | 1,022 | 924 | +10.6% |
| Vraylar · Non Us | 2 | 2 | 0.0% |
| Vraylar · US | 1,020 | 922 | +10.6% |
| Vyalev · Neuroscience | 183 | 44 | +315.9% |
| Vyalev · Non Us | 97 | 43 | +125.6% |
| Comprehensive Income | 2,246 | 387 | +480.4% |
| Net Income Loss Available To Common Stockholders Basic | 1,806 | -32 | +5743.8% |
| Interest Expense | 714 | 702 | +1.7% |
Balance Sheet
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 5,229 | 5,524 | -5.3% |
| Short-Term Investments | 28 | 31 | -9.7% |
| Accounts Receivable | 12,589 | 10,919 | +15.3% |
Show Counterparty Name breakouts |
|||
| Janssen Biotech, Inc · Collaborative Arrangement | 218 | 237 | -8.0% |
| Inventory | 4,951 | 4,181 | +18.4% |
| Prepaid Expense And Other Assets | 6,265 | 4,927 | +27.2% |
| Total Current Assets | 29,062 | 25,582 | +13.6% |
| Non-Current Assets | |||
| Long Term Investments | 268 | 279 | -3.9% |
| Property, Plant & Equipment | 5,628 | 5,134 | +9.6% |
| Goodwill | 35,640 | 34,956 | +2.0% |
| Other Non-Current Assets | 10,721 | 9,142 | +17.3% |
| Total Assets | 133,960 | 135,161 | -0.9% |
| Operating Lease Right-of-Use Assets | 737 | 723 | +1.9% |
| Intangible Assets | 47,360 | 54,866 | -13.7% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 46,390 | 53,175 | -12.8% |
| Licensing Agreements | 970 | 1,691 | -42.6% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 52,641 | 60,068 | -12.4% |
| Current Liabilities | |||
| Short Term Borrowings | 2,499 | — | — |
Show Short Term Debt Type breakouts |
|||
| 364 day Term Loan Credit Agreement | 2 | — | — |
| Commercial Paper | 499 | — | — |
| Long Term Debt And Capital Lease Obligations Current | 6,056 | 6,804 | -11.0% |
| Accounts Payable And Accrued Liabilities Current | 34,734 | 31,945 | +8.7% |
Show Counterparty Name breakouts |
|||
| Janssen Biotech, Inc · Collaborative Arrangement | 189 | 282 | -33.0% |
| Total Current Liabilities | 43,289 | 38,749 | +11.7% |
| Accounts Payable | 3,592 | 2,945 | +22.0% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 2,389 | 2,579 | -7.4% |
| Other Non-Current Liabilities | 32,569 | 30,129 | +8.1% |
| Long-Term Debt | 64,503 | — | — |
| Operating Lease Liabilities | 689 | 697 | -1.1% |
| Accrued Income Taxes Noncurrent | 364 | 1,261 | -71.1% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 58,941 | 60,340 | -2.3% |
| Minority Interest | 42 | 39 | +7.7% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 18 | 18 | 0.0% |
| Treasury Stock Value | -9,146 | -8,201 | -11.5% |
| Additional Paid In Capital Common Stock | 22,495 | 21,333 | +5.4% |
| Retained Earnings | -15,493 | -7,900 | -96.1% |
| Accumulated Other Comprehensive Income | -1,144 | -1,925 | +40.6% |
| Total Stockholders' Equity | -3,270 | 3,325 | -198.3% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -3,228 | 3,364 | -196.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest | -243 | -664 | +63.4% |
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -633 | -2,114 | +70.1% |
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest | 154 | 304 | -49.3% |
| Accumulated Other Comprehensive Income | -1,144 | -1,925 | +40.6% |
| Additional Paid In Capital | 22,495 | 21,333 | +5.4% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -1,144 | -1,925 | +40.6% |
| Common Stock | 18 | 18 | 0.0% |
| Net investment hedging activities | -422 | 549 | -176.9% |
| Noncontrolling Interest | 42 | 39 | +7.7% |
| Retained Earnings | -15,493 | -7,900 | -96.1% |
| Treasury Stock Common | -9,146 | -8,201 | -11.5% |
| Total Liabilities & Equity | 133,960 | 135,161 | -0.9% |
Cash Flow Statement
| Metric | YTD Q4 2025 | YTD Q4 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 203 | 206 | -1.5% |
| Amortization Of Intangible Assets | 1,784 | 1,896 | -5.9% |
| Deferred Income Taxes | -385 | -767 | +49.8% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 1,406 | 279 | +403.9% |
| Payment For Contingent Consideration Liability Operating Activities | -681 | -539 | -26.3% |
| Stock-Based Compensation | 157 | 164 | -4.3% |
| Non Cash Litigation Reserve Adjustments Net Of Cash Payments | 136 | 167 | -18.6% |
| Other Non-Cash Items | -9 | 12 | -175.0% |
| Change in Accounts Receivable | 162 | 387 | -58.1% |
| Change in Inventory | -25 | -128 | +80.5% |
| Change in Prepaid & Other Assets | -658 | -100 | -558.0% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -598 | 1,247 | -148.0% |
| Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable | 646 | -1,803 | +135.8% |
| Net Cash from Operations | 5,218 | 7,048 | -26.0% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | 0 | 0 | — |
| Payments To Acquire Other Investments | -1,161 | -1,792 | +35.2% |
| Capital Expenditures | -329 | -291 | -13.1% |
| Payments To Acquire Marketable Securities | -6 | -27 | +77.8% |
| Proceeds From Sale Maturity And Collections Of Investments | 34 | 39 | -12.8% |
| Other Investing Activities | -1 | 197 | -100.5% |
| Net Cash from Investing | -1,463 | -1,874 | +21.9% |
| Financing Activities | |||
| Proceeds From Short Term Debt | 0 | 0 | — |
| Repayments Of Other Short Term Debt | -791 | 0 | — |
| Proceeds From Issuance Of Long Term Debt | 0 | 2,000 | -100.0% |
| Repayments Of Long Term Debt And Capital Securities | -8 | -5,762 | +99.9% |
| Payments Of Dividends | -2,911 | -2,752 | -5.8% |
| Share Repurchases | -3 | -358 | +99.2% |
| Proceeds From Stock Options Exercised | 48 | 10 | +380.0% |
| Proceeds From Payments For Other Financing Activities | -1 | 1 | -200.0% |
| Net Cash from Financing | -4,166 | -6,861 | +39.3% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 11 | -46 | +123.9% |
| Net Change in Cash | -400 | -1,733 | +76.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5,229 | 5,524 | -5.3% |
Values in millions USD. Source: SEC EDGAR 10-K filing.